Skip to main content

Market Overview

Fred's Deal With Walgreen's A Positive, But Price Spike Leaves Little Upside From Here

Share:
Fred's Deal With Walgreen's A Positive, But Price Spike Leaves Little Upside From Here

MKM Partners is positive on Fred's, Inc. (NASDAQ: FRED)’s deal to buy 865 Rite Aid Corporation (NYSE: RAD) stores for $950 million in cash as part of “forced divestiture” required by the FTC following Walgreens Boots Alliance Inc (NASDAQ: WBA)’s acquisition of Rite Aid.

Why Sidelined?

But, the brokerage remains Neutral on Fred’s shares, as it believes the 81 percent surge in stock price has priced in much of the potential opportunity. It also sees a fair amount of integration risk, given Fred's poor operational performance.

Nevertheless, the deal will more than double Fred's size (currently 650 stores) and will make the company the third largest U.S. drugstore chain next to Walgreen's and CVS Health Corp (NYSE: CVS). Walgreen's, which operates nearly 13,000 stores globally, will add another 3,735 once it acquires Rite Aid, while CVS operates 9,700+ stores.

It's Definitely A Solid Deal

Analyst Patrick McKeever called Fred’s deal good, as it is effectively paying $1.1 million per store for stores that generate $5 million–$7 million in annual sales and $275,000–$300,000 in EBITDA.

“The mid-point of the EBITDA range implies a margin of 4.8 percent, well below the 7+ percent margins of Walgreens and CVS but dramatically above Fred's 1–2 percent rate,” McKeever wrote in a note.

McKeever expects the acquisition to produce about $300 million in EBITDA in year one, including $250 million from the Rite Aid stores and $50 million from Fred's assuming no major synergies.

As such, the analyst raised his fair value estimate on Fred’s shares to $22 from $9.

At last check, shares of Fred’s were down 1.44 percent at $19.90. Shares of Walgreen's were down 0.57 percent at $85.79, while Rite Aid shares were down 0.99 percent at $8.52.

Image Credit: By Michael Rivera (Own work) [CC BY-SA 4.0], via Wikimedia Commons

Latest Ratings for CVS

DateFirmActionFromTo
Feb 2022Raymond JamesDowngradesStrong BuyOutperform
Dec 2021Tigress FinancialMaintainsBuy
Dec 2021MizuhoMaintainsBuy

View More Analyst Ratings for CVS

View the Latest Analyst Ratings

 

Related Articles (FRED + CVS)

View Comments and Join the Discussion!

Posted-In: Analyst Color M&A News Price Target Reiteration Retail Sales Asset Sales Analyst Ratings Best of Benzinga

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com